ZIOPHARM (ZIOP) Starts ZIO-201 Phase 2 in Germ Cell Tumors
ZIOPHARM Oncology, Inc. (NASDAQ: ZIOP) announced the start of a multicenter, single arm Phase 2 investigator-sponsored study of palifosfamide (ZIO-201) in patients with recurrent metastatic germ cell (testicular and ovarian) tumors who have relapsed on initial platinum-based therapy and high dose chemotherapy, or patients who are not eligible for...
Get Alerted When News Hits On This Stock - FREE!